In GB590's second-unit framework application, a utilitarian count and a rights analysis disagree about one patient's dose and agree on a published protocol any eligible patient could enter. Searches like "gb 590 unit 2 assignment example", "gb590 unit 2 sample" and "gb590 unit 2 example" land here.
What a finished GB590 Unit 2 ethical framework application looks like
Five to six pages in five parts, with a short facts section first. The composite company has forty employees, one investigational antiviral in a Phase 2 trial, and [210] doses manufactured for enrolled patients; a transplant recipient with a resistant infection does not meet the trial's criteria, and her family's campaign has reached national news. A one-paragraph legal note follows: the federal Right to Try Act of 2018 and FDA's expanded access pathway both permit a manufacturer to supply the drug, and neither requires it. The utilitarian section counts who gains and loses if one dose is released, including trial participants and future patients. The rights section asks what claim the patient holds against the firm. A comparison and a recommendation close the paper.
How a GB590 Unit 2 example is structured
The two frameworks run in sealed sections, so neither borrows the other's conclusion. The utilitarian section works in counts rather than sympathy: one dose is under half a percent of supply, but granting a publicized request tends to multiply requests, pulls clinical staff from trial sites and exposes the program to an adverse event outside controlled conditions, any of which could delay approval for many later patients. On a narrow count the dose should go; on the wider count, precedent dominates. The rights section separates a right not to be obstructed, which the law now largely honors, from a claim on the company's supply, which the patient lacks. What she does hold is a claim to equal consideration with quieter patients. The comparison shows where the frameworks part, and the recommendation follows the rights constraint.
Forty staff, 210 doses, one plea
A Phase 2 antiviral, a patient outside the trial's criteria and a family campaign carried by national news, set down without adjectives.
Permitted, never required
The Right to Try Act of 2018 and FDA expanded access allow the company to supply the drug; neither obliges it to.
The count, narrow and wide
One dose weighed against precedent, diverted staff and an uncontrolled adverse event, showing how widening the count reverses its answer.
Which right, held against whom
Freedom from obstruction separated from a claim on private supply, leaving equal consideration as the right the patient actually holds.
An open protocol, fifteen doses
Published criteria, an outside physician panel and a capped cohort, with the patient assessed under them within days rather than by headline.
Where marks go in GB590 Unit 2
Graders read this unit for application, and its commonest shortfall explains both frameworks well, then applies neither and closes on compassion. A utilitarian section that counts only the patient and her family has not done the count; the trial participants and later patients are where the weight sits. Rights language gets misused when the paper asserts a right to the drug without saying who holds the duty, which here would be a private company with no obligation under either federal pathway. Collapsing the frameworks into agreement too early hides the one place they differ, the individual dose. Recommendations that grant the request with no criteria for the next family, or refuse with no process at all, answer only half the case. Stating that the law requires supply misreads it.
Get a GB590 Unit 2 example written to your instructions
Your first request is free. For Unit 2, the business case, the two frameworks your instructions name and the rubric are enough to produce a paper where each framework keeps its own section, the two are compared where they diverge, and a recommendation grows out of that comparison, within 24-48h. The biotech and patient are composites, and nothing here is medical guidance.
GB590 Unit 2 questions, answered
Why run the frameworks in separate sections?
So neither can quietly borrow the other's conclusion. Blended papers often slide from tallying harms to asserting entitlements inside one paragraph, and the verdict ends up resting on whichever came last. The GB590 example seals each section, lets each reach its own answer on the single dose, and compares only afterward, which keeps the final choice traceable.
Does the paper name a real company?
Only as a reference point. The main case is a composite, and one sentence recalls the 2014 Chimerix episode, in which a refusal to release an unapproved antiviral was reversed within days through a small open-label study after a public campaign. Your section may assign a different real case, and the sample would state its facts as reported.
What does the law say a company must do with expanded access requests?
Very little beyond transparency. Federal law since 2016 requires sponsors of investigational drugs for serious conditions to publish their policy on evaluating expanded access requests, and neither that pathway nor the Right to Try Act compels supply. The example states this in a short legal note, so the ethical analysis carries the decision rather than a misread statute.